HAE vs. BSX: Which Stock Is the Better Value Option?

Core Insights - Both Haemonetics (HAE) and Boston Scientific (BSX) have a Zacks Rank of 2 (Buy), indicating positive earnings outlooks for both companies [1] - HAE has a P/B ratio of 4.77, while BSX has a P/B ratio of 5.71, suggesting HAE may be more attractively valued [2] - HAE's Value grade is B, compared to BSX's D, indicating HAE is viewed more favorably by value investors [5] Valuation Metrics - HAE has a forward P/E ratio of 19.75, significantly lower than BSX's forward P/E of 33.72, indicating HAE may be undervalued relative to BSX [8] - HAE's PEG ratio is 1.65, while BSX's PEG ratio is 2.69, further supporting the notion that HAE offers better value based on expected earnings growth [8] Investment Considerations - Investors in the Medical - Products sector may find HAE to be a superior value option compared to BSX based on the discussed valuation metrics [6][9]